Management of secondary hyperparathyroidism inpatients with chronic kidney disease undergoing dialysis in Togo;Prise en charge des hyperparathyroïdies secondares chez des patients dialysés au Togo

Medecine et sante tropicales

Volumn 22, Issue 1, 2012, Pages 65-68

  Dosseh, E D ^a   Kassegne, I ^a   Sakiye, K ^a   Adambounou, A ^a   James Yawovi, E ^a   Djagadou, K ^a   Kossidje, K ^a   Ayite, Ae ^a  

^a UNIVERSITÉ DE LOMÉ   (Togo)

Author keywords

Chronic renal failure; Secondary hyperparathyro dism; Togo

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; FEMALE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM; TOGO;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TOGO; YOUNG ADULT;

EID: 84864526915     PISSN: 22613684     EISSN: 22612211     Source Type: Journal    
DOI: 10.1684/mst.2012.0027     Document Type: Article

References (12)

1. Bricker NS, Slatopolsky E, Reiss E, Avioli LV. Caclium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med 1969; 123: 543-553.
2. Block G, Klassen P, Kim J. Relationship between serum calcium and mortality risk in hemodialysis patients. Am J Kidney Dis 2003; 41: A16.
3. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138.
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
5. Buargub MA, Nabulsi MF, Shafeh TA. Prevalence and pattern of renal osteodystrophy in chronic hemodialysis patients: a cross sectional study of 103 patients. Saudi J Kidney Dis Transpl 2006; 17: 401-407.
6. Block G, Danese M, Kim J. Elevated PTH and Ca X P levels are associated with increased hospitalization in hemodialysis patients. Am J Kidney Dis 2003; 41: A3.
7. Drüeke TB TM, Thorney-Brown D, Rostand SG. Calcifications extraosseuses chez le patient insuffisant renal chronique. In Actualites nephrologiques, Jean Hamburger. Paris, Flammarion Medecine-Sciences, 2000, pp. 53-80.
8. Qi Q, Monier-Faugere M, Geng Z, Malluche H. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-631.
9. Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005; 63: 284-289.
10. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141-2156.
11. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004; 65: 1914-1926.
12. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800.